The role of liquid biopsy in predicting post-operative recurrence of non-small cell lung cancer

Hengrui Liang¹,²,³*, Jianbin Huang³*, Bo Wang³*, Zhichao Liu³*, Jianxing He¹,², Wenhua Liang¹,²

¹Department of Thoracic Surgery and Oncology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; ²China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China; ³Nanshan School, Guangzhou Medical University, Guangzhou 510120, China

Contributions: (I) Conception and design: All authors; (II) Administrative support: J He; (III) Provision of study materials or patients: W Liang; (IV) Collection and assembly of data: H Liang, J Huang; (V) Data analysis and interpretation: H Liang, Z Liu, B Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally in this work.

Correspondence to: Jianxing He; Wenhua Liang. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China; China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou 510120, China. Email: drjianxing.he@gmail.com; liangwh1987@163.com.

Background: Radical resection is the cornerstone for patients with early stage of non-small cell lung cancer (NSCLC). However, fatal disease recurs in about 30–70% of resected cases. The circulating tumor cells (CTCs) is one of the main causes of recurrence of cancer. Circulating tumor DNA (ctDNA) is also a potential predictive biomarker of recurrence in patients with early stage NSCLC. A meta-analysis was conducted to identify the prognostic value of the CTCs and ctDNA in predicting the disease recurrence after surgery of NSCLC patients.

Methods: Electronic databases were comprehensively searched for eligible studies. A random effects model was used. The primary endpoint was the hazards ratio (HR) for the disease-free survival (DFS) between CTCs/ctDNA positive and negative groups. The relative risks (RR) of one and two-year recurrence rate between CTCs/ctDNA positive and negative groups were also calculated.

Results: A total of 5 studies involving 351 patients were included, in which 3 were studies on CTCs and 2 were ctDNA. Our result revealed that positive peripheral blood CTCs (HR, 3.37; 95% CI: 2.28–4.96; P<0.001) and ctDNA (HR, 8.15; 95% CI: 2.11–31.50; P=0.002) indicated poor prognosis for DFS. One (68% vs. 18.2%; RR 3.28; P<0.001) and two (76% vs. 44%; RR 1.80; P=0.06) years recurrence rate were higher in CTCs positive group compared with the negative group, respectively. The same result was also observed in ctDNA positive versus negative groups of 1 (77.9% vs. 8.3%; RR 9.05; P=0.001) and 2 (85.6% vs. 8.3%; RR 9.63; P<0.001) years recurrence rate.

Conclusions: Both postoperative CTCs and ctDNA are promising predictive biomarkers of early tumor recurrence in NSCLC patients. In addition, detection based on ctDNA seems to be more sensitive than CTCs.

Keywords: Non-small cell lung cancer (NSCLC); circulating tumor cell (CTC); circulating tumor DNA (ctDNA); recurrence

doi: 10.21037/jtd.2018.04.08
View this article at: http://dx.doi.org/10.21037/jtd.2018.04.08
Introduction

Radical resection is the cornerstone for patients with early stage of non-small cell lung cancer (NSCLC). NCCN guidelines have recommended that patients require follow-up with CT ± contrast scans every 6 months for the first 2 to 3 years after radical surgery of NSCLC (1). However, tumor relapse occurs in about 30–70% of resected cases (2). Early detection of recurrence of primary lung cancer after surgery is associated with improved outcomes and survival in patients at early stage. With the rapid development of precision medicine and individual therapy in lung cancer, liquid biopsy, a very promising detection method of oncological research, could predict recurrence 1 to 2 years earlier than radiographic progression (3).

Circulating tumor cells (CTCs), originating from the tumor site and migrating to peripheral blood, is one of the “liquid biopsy” approach and a source of valuable tumor markers (4). Tumor cells can often be found in the circulation of patients with advanced cancer. The presence of CTCs is consistently associated with poor outcome with shorter disease free survival (DFS) (5), lower progression-free survival (PFS) and overall survival (OS) (6,7).

Circulating tumor DNA (ctDNA) is also a potential predictive biomarker of recurrence in patients with early stage NSCLC (8). ctDNA can reflect the tumor burden, and its levels decreased after radical surgery and generally increased as new lesions became apparent upon radiological examination, which may help to provide the genetic follow-up data (9). Postoperative ctDNA detection of breast and colorectal tumors has been shown to be used as an indicator to identify patients at high risk of recurrence and the presence of ctDNA after completion of resection was associated with an inferior recurrence-free survival (10,11).

Recently, an increasing interest has been focused on the predictive value of CTCs and ctDNA, which may serve as new indicators for discovering recurrence and metastasis of tumors. With the aim of evaluating the predictive value of the CTCs and ctDNA on the recurrence of tumor, we conducted a meta-analysis comparing the DFS for post-operative NSCLC patients.

Methods

Search strategy

The following electronic databases were searched up to 13 January 2018: The Cochrane Library, PubMed, Science Direct, Google Scholar, Embase. In order to search the eligible studies, we set no restrictions for language or publications status. The following words were used as algorithms: non-small cell lung cancer, CTCs, ctDNA, DFS, recurrence. To locate trials that were unpublished or failed to be identified by keyword searching, the body and reference sections of the studies were checked to find potentially eligible articles. We also scanned the poster and presentation of international conference to capture the target.

Study selection

All the studies were selected on the following inclusion criteria: (I) studies that reported the recurrence of the early stage NSCLC; (II) CTCs/ctDNA were used to diagnose disease and evaluate the tumor relapse; (III) studies in which the sufficient information are provided to estimate hazard ratio (HR) of DFS and 1 or 2 years recurrence rate. The exclusion criteria was as following: (I) reviews, letters, case reports, expert opinion, editorials; (II) all publications regarding in vitro/ex vivo studies, cell lines, and human xenografts; (III) studies in which the same population or overlapping data were used.

Although the language restrictions were not set initially, we only conducted the review of the studies published in English language. After the exclusion of non-relevant and redundant publications from different databases, we collected studies and evaluated in full-text by taking the inclusion and exclusion criteria mentioned above.

Data extraction

The eligible data was independently reviewed and extracted by two authors (Bo Wang, Zhichao Liu). Once there were disagreements the third author (Hengrui Liang) was consulted. Information was recorded into a table format from the all studies: the first author name, year of publication, sample source, number of CTC/ctDNA positive and negative cases, follow up (month), gender, age, smoker, adenocarcinoma, tumor size, cancer tumor node metastasis stage, PET-CT (SUV). We also conducted investigation of heterogeneity which was evaluated to determine whether the data from studies could be used in meta-analysis.

Quality assessment of the included studies

The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines were followed in demonstrating the standard methodology and results (12). Quality assessment of included studies was assessed using the Joanna Briggs Institute Prevalence Critical Appraisal Tool to assess the quality of the studies. Any disagreement was resolved via discussion among the authors (13).

**Statistical analysis**

We used STATA12.0, Review Manager5.3 to analyze the data. A random effects model was used as the statistical heterogeneity assessment by using the Cochrane's Q statistic and I² test (14). The primary endpoint was the hazards ratio (HR) for the DFS between CTCs/ctDNA positive and negative groups. HR was calculated based on the method of Parmar et al.'s study if it was unavailable from original paper (15,16). The relative risks (RR) of one and two year recurrence rate between CTC/ctDNA positive and negative groups were also calculated.

**Results**

**Identification of relevant studies**

Initially there were 457 records identified through database searching together with 13 additional records from other sources. After duplicating there were 466 records (including 367 records related to CTCs and 99 records related to ctDNA) remained and screened by two authors independently. Ultimately, 5 eligible articles (3 were studies on CTC and 2 were on ctDNA) included in and 351 patients were involved totally (17-20) (Figure 1).

**Study characteristics**

Table 1 noted the detailed information of included studies. The studies were conducted in two different countries with the periods ranged from 2001 to 2017. One study related to ctDNA was a conference abstract. Two articles were about CTCs and the others focused on ctDNA. The detection rate of CTCs and ctDNA in all studies are 57.3% and 56.9%, respectively. All studies gained 7 to 10 stars in study quality assessment on a scale of 0 to 10 with Joanna Briggs Institute Prevalence Critical Appraisal Tool.

**The correlation of CTCs/ctDNA with tumor recurrence in post-operative NSCLC patients**

Both positive peripheral blood CTCs (HR, 3.37; 95%
CI: 2.28–4.96; P<0.001) and ctDNA (HR, 8.15; 95% CI: 2.11–31.50; P=0.002) indicated poor prognosis for tumor relapse, with the use of random effect model (Figure 2).

The correlation of CTCs/ctDNA with 1- and 2-year recurrence rate

The RR of 1 (68% vs. 18.2%; RR 3.28; P<0.001) and 2 (76% vs. 44%; RR 1.80; P=0.06) years recurrence rate were higher in CTC positive group compared with the negative group, respectively. The same result were also observed in ctDNA positive versus negative groups of 1 (77.9% vs. 8.3%; RR 9.05; P=0.001) (Figure 3) and 2 (85.6% vs. 8.3%; RR 9.63; P<0.001) (Figure 4) years recurrence rate.

Discussion

Tumor recurrence after radical surgery of NSCLC patients is common. Regular low-dose computed tomography (LDCT) examination is recommended to monitor the tumor relapse, but there is no clinical biomarker so far that could better stratify high-risk individuals. Our pooled data indicated that positive CTCs (HR, 3.37; P<0.001) and ctDNA (HR, 8.15; P=0.002) indicated worse DFS of NSCLC patients. Higher recurrence rates were observed in CTCs/ctDNA positive group compared with the negative group both at 1 and 2 years after surgery. Thus, the dynamic monitoring of CTCs/ctDNA might be suggested as an evidence for predicting the neoplasm relapse. In addition, the higher HR value in ctDNA studies than in CTC studies, although not a direct comparison, suggested higher sensitivity of ctDNA in detecting micro-residuals.

With the development of molecular diagnosis and target therapy of NSCLC in the past few years, tumor-specific genomic and epigenetic alterations are usually recognized based on tissue either from surgery or biopsy. However, because of temporal and spatial heterogeneity, molecular information based on tissue is inaccuracy and inconvenience (21). Liquid biopsy therefore has been widely concerned by scientists owing to its obvious clinical advantages. CTCs are cells that from a primary tumor and are carried around the body in the circulation, which thus are recognized as seeds for the subsequent metastases in vital distant organs, leading to cancer-related deaths. ctDNA is tumor-derived small fragments of nucleic acid in the bloodstream, which can reflect the entire genetic profile of a tumor. Both CTCs and ctDNA have shown the
potential to be a promising clinical biomarker for patient stratification, early diagnosis, disease monitoring and guide for therapy (22).

Nearly 30–70% NSCLC patients had surgery would eventually experience tumor recurrence or metastasis. Adjuvant chemotherapy is commonly recommended to high-risk stage IB and II–IIIA NSCLC patients after surgery owing to the significantly increase of OS rate, but only 4% to 5% of targeted patients would get profit (23). For patients those who harbor EGFR mutation, EGFR-TKIs
could also be another candidate (24). However, it is also known that systemic adjuvant therapies own toxicities such as infection, neuropathy and secondary malignant tumor which can even lead to premature deaths. Unfortunately, neither guideline nor in the clinical trials, patients were not selected by clinical biomarkers in predicting their potential risk of recurrence, which probably since there are no enough tissue sample after radical surgery for monitoring the relapse, and liquid biopsy might be helpful.

Increasing evidence suggests that early recurrence of tumor in resected NSCLC patients may arise from CTCs that shed from the primary tumor into the vasculature or lymphatics since the beginning of the malignant process and are carried around the body in the circulation (17-19). Detection of peripheral CTCs may identify recurrence high-risk patients and could be a more specific indication for adjuvant therapy. There are several studies that evaluate the prognostic significance of CTCs detection in resected NSCLC cases after surgery. Hofman and colleagues (5) found the detection rate of CTCs in NSCLC patients after surgery was 49%, which is similar to ours. Furthermore, using ISET technique, they indicated that CTCs count of 50 or more is the independent negative factor for the disease relapse and OS. Another study by Rolle et al. (25) reported 30 patients with post-surgery NSCLC were examined using the MAINTRAC technique. They observed CTCs in 2 weeks and 5 months after surgery. The CTCs count was compared to prognosis and patients with continuously increasing in median CTC-count post-operatively were shown to be at a higher risk of tumor relapse. Sawabata et al (4) observed that CTCs disappeared about 10 days after surgery was performed. In fact, it is well known that a majority of CTCs can be shed into the vascular or lymph system during operation, but it is still uncertain whether this part of CTCs are involved in the subsequent recurrence or metastasis. Thus Bayarri-Lara et al. (17) thought that in order to get a real assessment of CTCs presence, detection must be performed at least 3 weeks after the operation.

cDNA, which carried whole genomic information, can be detected in the peripheral blood of patients with advanced cancer, acting as a potential noninvasive source to characterize the somatic mutation features of NSCLC (8). However limited data are available on whether ctDNA analyses would be applicable to early cancer, especially in monitoring tumor relapse, in part because the low tumor burden of micro-metastatic disease after radical surgery, which makes detection of ctDNA challenging. With the fast development of sequencing technique, several scientists tempted to characterize the feature the dynamic change of ctDNA in early stage of malignant tumor. In a prospective cohort of early breast cancer patients, detection of ctDNA in plasma after curative treatment, either at a single postsurgical time point or with serial follow-up plasma samples, predicted metastatic or relapse with high accuracy.

Figure 4 The correlation of CTCs/ctDNA with two-year recurrence rate. CTCs, circulating tumor cells; ctDNA, circulating tumor DNA.

<table>
<thead>
<tr>
<th>Study ID</th>
<th>CTCs</th>
<th>Detection Rate</th>
<th>95% CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbosh et al. (2017)</td>
<td>8.57</td>
<td>(1.32, 5.71)</td>
<td>39.90</td>
<td></td>
</tr>
<tr>
<td>Chaudhuri et al. (2017)</td>
<td>10.40</td>
<td>(2.26, 47.70)</td>
<td>60.10</td>
<td></td>
</tr>
<tr>
<td>Subtotal (I-squared = 0.0%, p = 0.875)</td>
<td>9.63</td>
<td>(2.95, 31.40)</td>
<td>100.00</td>
<td></td>
</tr>
<tr>
<td>Lara et al. (2016)</td>
<td>2.35</td>
<td>(1.16, 4.75)</td>
<td>29.70</td>
<td></td>
</tr>
<tr>
<td>Crosbie et al. (2016)</td>
<td>2.80</td>
<td>(1.08, 7.25)</td>
<td>22.47</td>
<td></td>
</tr>
<tr>
<td>Hofman et al. (2011)</td>
<td>1.25</td>
<td>(1.11, 1.41)</td>
<td>47.84</td>
<td></td>
</tr>
<tr>
<td>Subtotal (I-squared = 70.0%, p = 0.036)</td>
<td>1.80</td>
<td>(0.98, 3.34)</td>
<td>100.00</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Weights are from random effects analysis.
They show that tracking of ctDNA mutation, especially driver or clone mutation, can detect minimal residual disease noninvasively and identify earlier high-risk patients of tumor relapse than the radiological or clinical recurrence. Tie et al. (11) used massively parallel sequencing-based assays to evaluate the ability of ctDNA to detect minimal residual disease in a prospective cohort of 230 stage II colon cancer patients. They concluded the same with previous study that ctDNA detection after surgery performed provided the direct evidence of residual disease and identifies patients at very high risk of recurrence. Compared with CTC, detection of which was restricted by the uneven distribution and rare existence as a complete form in the blood, ctDNA should theoretically have higher sensitivity. This was supported by our current results in terms of HR value comparison. However, limited in the sequencing technique, the false negative rate of ctDNA detection is still high, which need to improve in the future.

Besides CTCs/ctDNA, some epigenetic markers like DNA methylation might also be a candidate to predict the recurrence of disease. With the help of genome-wide array assessment, Kitchen and colleagues (26) performed a study in exploring the novel DNA methylation markers of clinical outcomes for bladder cancer. They found hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HR-NMIBC recurrence and progression within 1 year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative predictive values. Another study also revealed a methylation-independent loss of MYO5B expression in colorectal cancer that matched disease progression (27). Their data identify MYO5B as a powerful prognostic biomarker in colorectal cancer, especially in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant chemotherapy. Hyper-methylated oncologic region in pancreatic cancer also could distinguish early stage I disease from normal tissue and was associated with worse prognosis (28). With the further promotion of technology and practice, tumor relapse could be better predicted in combination of radiological examination, genetic and epigenetic molecular biomarker, and thus the corresponding therapeutic plan could be given timely.

We acknowledge several limitations to our study. First, the small number of studies and samples is the primary limitation of the present article. Second, follow-up time is not enough in all included studies another shortcoming. Third, there is no data available of CTCs/ctDNA both before and after surgery. Last, we were unable to calculate the dose-response curve of the prognostic effect of CTCs/ctDNA. Further studies should focus more on the dynamic change of liquid biopsy result and provide a precise treatment recommendation.

Conclusions
Our study suggested both CTCs and ctDNA might be predictive biomarkers of early tumor recurrence in patients with operable NSCLC. Detection based on ctDNA seems to be more sensitive than CTCs. More prospective clinical study should be done to validate the practicability and economic efficacy of liquid biopsy in predicting tumor relapse.

Acknowledgements
Funding: Chinese National Natural Science Foundation (Grant No. 81501996); Key Project of Guangzhou Scientific Research Project (Grant No. 201804020030); Guangdong Doctoral Launching Program (Grant No. 2014A030310460); Doctoral Launching Program of Guangzhou Medical University (Grant No. 2014C27); and Key Project of Livelihood Technology of Guangzhou (2011Y2-00024).

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

References